
Obstructive HCM Care Hinges on Teams, Pharmacy, and Drug Access
Key Takeaways
- Delayed HCM recognition reflects symptom overlap and absent resting obstruction; systematic routing from primary care, ECG flags, and cardiac MRI can differentiate phenocopies such as amyloidosis and Fabry disease.
- Guideline-concordant sequencing starts with nonvasodilating beta-blockers, then individualizes septal reduction vs cardiac myosin inhibition, incorporating patient trade-offs and emerging comparative data such as MAPLE.
Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM treatment.
Treating obstructive hypertrophic cardiomyopathy (oHCM) well now depends as much on team design, documentation, and medication access as it does on choice of therapy. Faculty described how their organizations are building multidisciplinary clinics, standardizing prior authorization (PA) paperwork, and widening the net for patients with HCM who remain undiagnosed or unmanaged, at The American Journal of Managed Care®’s
Why Does HCM Go Unrecognized for So Long?
Moderator John Romme, MD, who specializes in advanced heart failure (HF) and transplant cardiology at Novant Health, opened by noting that HCM is estimated to affect about 1 in 327 people and that approximately half of patients show no obstructive gradient on a resting echocardiogram. Symptoms overlap with HF, hypertension, and amyloidosis, which makes the diagnosis easy to miss.
Zachary Garrett, MD, also of Novant, noted that some of the patients most likely to be missed have no symptoms at all. They may have a family history of sudden death or an abnormal electrocardiogram noted in a primary care office, and he said they need to be identified and funneled to appropriate testing and centers. He added that cardiac MRI can help separate HCM from look-alike conditions, such as amyloidosis and Fabry disease.
An HF cardiologist on the panel said genetic testing was hard to arrange because of long academic-center waiting lists until their health system partnered with a company that offered testing at a more reasonable cost. Garrett said Novant has explored artificial intelligence (AI) screening tools but has not adopted one, citing cost, an ECG-only HCM screen, and limited downstream testing supplies. He also warned of flooding clinics with false positives when the positive predictor value is low.
How Are Teams Sequencing oHCM Treatment?
Garrett said his group largely follows the 2024 American Heart Association/American College of Cardiology
When gradients are very high, the HF cardiologist explained, their practice starts a beta-blocker, give fluid guidance, and brings the patient back in a month to discuss a CMI. In these conversations, they added, data from the head-to-head MAPLE trial (
Garrett also adjusts patients’ other medications, such as afterload-reducing agents and diuretics, for HCM. Drug interactions can steer the CMI choice: Garrett has preferred aficamten for a renal transplant patients on tacrolimus and sirolimus, although insurers sometimes dictate the agent. He has also used CMIs for patients whose obstruction returned after myectomy, sparing some a second sternotomy. A chief pharmacy officer who attended pointed out that documentation drives access. Payers expect to see step therapy in the record, so clinicians should start a beta-blocker and document it even when they suspect it will not be enough.
What Stands Between Patients and CMI Therapy?
Some of the pharmacy faculty assembled said access, not clinical performance, often decides which agent a patient receives. “I think for our patients, unfortunately, it’s what can we get access to and [what] can they afford, and that’s how the pathway goes,” said Amanda Ball, PharmD, BCPS, BCCCP, pharmacy clinical manager, Clinical and Patient Care Services, Duke Pharmacy. “This is a great opportunity to partner with your pharmacy team.”
She added that clinical pharmacists can coordinate with specialty pharmacy, confirm affordability even after approval, and identify community support resources, work that repeats each year. The chief pharmacy officer in attendance said that manufacturers place CMIs in limited distribution drug categories so that only certain pharmacies can dispense them. Keeping dispensing in-system gives prescribers visibility into whether a patient received a drug. PA requests add more friction because each manufacturer uses its own format, and the formats change every year.
“But the more that we can try to standardize the documentation, the better and faster we were going to be to get things approved,” the chief pharmacy officer explained, adding that payers also use AI to uncover reasons for denial.
Ball described the work behind each request. “You don’t feel that barrier, but there’s a lot of movement under the water that’s trying to make that happen that you may just not know about,” she said.
For patients who live far away, the HF cardiologist said the practice obtains an echocardiogram locally and holds a video visit about once per year.
How Are Multidisciplinary HCM Teams Structured?
Garrett’s HCM team includes 2 advanced practice providers (APPs) and 2 to 3 clinical pharmacists, with electrophysiology and HF joining for specific cases in what he described as a hub-and-spoke pattern. Pharmacists have caught unreported supplements.
“I can ask patients 50 times, and then they go see the pharmacist and the pharmacist is like, ‘Well, here’s all of their herbal medications they’re on that you asked them about that they said no, and every single one of them interact’,” he said.
At the HF cardiologist’s clinic, a nurse coordinator and a pharmacist have taken on HCM alongside other duties. Convening a full team is harder in a community setting. “Sometimes we have a harder time getting everyone in the same room and having everyone have that same level of expertise with the volume of HCM, because in a community setting, we’re not seeing buckets of patients,” they said.
At Duke, Ball said, patients who have HCM are referred to HF clinical pharmacists, who run independent schedules and take over follow-up visits that do not need an APP or a physician. Because these pharmacists see the full range of patients with HF, Ball hopes to explore a dedicated resource spanning amyloidosis and oHCM. The chief pharmacy officer described a similar setup, with referrals often driven by drug cost, and asked whether lifetime drug spending, put at approximately $100,000/year should factor into choosing between medication and surgery under
Where Do Faculty Want to Go Next?
Garret’s group is focusing on continuing education for cardiologists, echocardiogram readers, and technologists so that more patients are recognized and routed correctly. The HF cardiologist said cardiology APPs work through a weekly curriculum that now includes HCM, and that flagging high-risk patients in the electronic health record could be a game changer. The chief pharmacy officer is considering bringing HCM to a primary care leadership meeting and wants to see more genetic testing earlier in the process.
One gap remained for Garrett. “With oHCM, we have good therapies; we have good pathways for those,” he said. “It’s the nonobstructive HCM cases that are difficult that come in. They still have very significant New York Heart Association class III symptoms and are really difficult to manage.”
Rommel said the patients he worries about most are not new referrals but those followed for years with a presumed diagnosis of hypertension. He asked how clinicians can revisit those cases. Faculty takeaways centered on practical steps: Document step therapy early, standardize the chart note that payers will read, be pharmacists in before the prescription is written, and give every clinician enough HCM awareness to refer on time.
Related to this article








